Business Wire

Summit Health Announces Internalization of Genomic Testing Cooperative State-of-The-Art Next Generation Sequencing DNA and RNA Profiling Tests for Tissue and Liquid Biopsy of ...

LAKE FOREST, Calif. & WOODLAND PARK, N.J.--(BUSINESS WIRE)--Summit Health, part of Village MD and Genomic Testing Cooperative (GTC), the global leader in RNA innovation, are excited to announce today ...
Nature

Precision proteomics: Next-Gen Protein Sequencing for proteoform detection and characterization

Proteins are central to cellular function, yet traditional proteomics methods—including mass spectrometry-based and affinity-based approaches—face challenges in resolving proteoforms, the distinct ...
Morningstar

Molecular Instruments® Continues RNA Imaging Leadership with Next-Generation miRNA/siRNA Detection and Clinical-Grade Ready-to-Use Kits

Both HCR™ Gold and HCR™ Pro now incorporate next-generation HCR™ HiFi architecture, enabling robust detection of small RNAs such as miRNA and siRNA with built-in automatic background suppression, ...
Healio

Most patients with advanced cancer do not undergo next-generation sequencing testing

Please provide your email address to receive an email when new articles are posted on . Real-world data show that only about 30% to 40% of patients with the most common cancers receive NGS testing.
News Medical

Elegen and Nutcracker Therapeutics to pilot first fully cell-free manufacturing process for RNA-based personalized cancer therapeutics

Elegen, a global leader in next-generation DNA manufacturing, and Nutcracker Therapeutics, a global leader in next-generation RNA design and manufacturing, today announced the launch of a pilot ...
TechSpot

New study reveals cybersecurity threats in next-gen DNA sequencing

A hot potato: Next-generation DNA sequencing (NGS) faces mounting scrutiny over its cyber vulnerabilities. While NGS has revolutionized fields ranging from cancer diagnostics to infectious disease ...
ascopubs.org

Adjuvant abemaciclib outcomes in routine clinical practice (experience of several Moscow centers).

Factors impacting treatment with abemaciclib + endocrine therapy in high risk early-stage HR+/HER2- breast cancer patients. Integration of next-generation RNA sequencing-based MammaPrint and BluePrint ...
ascopubs.org

Ethnic differences in nonalcoholic fatty liver disease (NAFLD) among women with early-stage breast cancer receiving endocrine therapy.

Integration of next-generation RNA sequencing-based MammaPrint and BluePrint analysis in clinical decision making: Performance evaluation in the first 1095 cases. This is an ASCO Meeting Abstract from ...